Team:SDU-Denmark/Tour34

From 2014.igem.org

(Difference between revisions)
 
(26 intermediate revisions not shown)
Line 2: Line 2:
<html>
<html>
-
<h3> Modelling </h3>
+
<h3> Safety </h3>
<p class='intro'>
<p class='intro'>
-
<font color="3397FE">An ambitious project of 73 differential equations</font>
+
<font color="3397FE">"With great power comes great responsibility!" - <b>Voltaire</b></font>
</p>
</p>
-
<h4>Two parts: Model of our own system and modelling database </h4>
+
<a class="popupImg alignRight" style="width:400px" target="_blank" href="https://static.igem.org/mediawiki/2014/d/d5/2014SDUsafety2.jpg" title="Working in the lab includes responsibilty.">
 +
  <img src="https://static.igem.org/mediawiki/2014/6/6d/2014SDUsafety1.jpg" style="width:400px" />
 +
</a>
<p>
<p>
-
<span class="intro">The modelling part of</span> our project is divided into two parts; the model of our own system and a suggestion of a modelling database being integrated on the iGEM website. Since the Edible coli project aims to make E. coli produce both the essential and the non-essential amino acids in a protein called OneProt, we decided to make a model of the biosynthesis of these amino acids in E. coli to detect bottlenecks in the system. This was a very ambitious projected and required a lot of research and time, since this biosynthesis of the amino acids consists of over 73 intermediates and thus would require at least 73 differential equations. After a long summer of modelling we came to the realization that since most teams in iGEM need to model pathways every year, it is a shame that every team needs to start from scratch when – most likely – the modelling of the enzymes in their system has already been modelled before in iGEM. This is when we came up with the idea of a modelling database, which would – just like the current parts registry – contain basic modelling “bricks” and these bricks would be uploaded from the teams that have already made them for their own project. Creating this system would allow future teams to make much more interesting and complex models since they could start from where previous teams left off and not from scratch. Below we elaborate on both the model of our own system and this modelling database idea with “proof of concept” examples of how the modelling registry could look and function and how a team would upload their modelling “bricks” to the registry.<br><br>
+
<span class="intro">The role of a synthetic biologist</span> involves the analysis of the biosafety of the systems designed. Biosafety is the prevention of an accidental or unintentional exposure to pathogens, and to analyze this it is useful to evaluate the risk involved in the project which can be expressed as
 +
<span class="sourceReference">“Risk= Hazard x Probability”.</span>
 +
<span class="tooltip">
 +
  <span class="tooltipHeader">Source:</span>
 +
    iGEM, 2013: Safety form Resources.
 +
<a href="https://2013.igem.org/Safety" target="_blank">(Link)</a></span><br><br>
</p>
</p>
-
<h4>Modelling of the biosynthesis of OneProt</h4>
+
<h4>Hazard</h4>
<p>
<p>
-
<span class="intro">As mentioned above we</span> wanted to model the biosynthesis of the essential and non-essential amino acids in the attempt to find bottlenecks in the system. We wanted to find out which amino acids would slow down the production of our protein based on the pathway using Michaelis-Menten kinetics and the differential equation solver <a href="http://www.berkeleymadonna.com/" target="_blank">Berkeley Madonna.</a> <br><br>
+
<span class="intro">To evaluate the potential hazardousness</span> of our project, we started by looking at the components of the system.
 +
Our main chassis, <i>E.coli</i> K12 MG1655 is a non-pathogen <i>E.coli</i>
 +
<span class="sourceReference">strain.</span>
 +
<span class="tooltip">
 +
  <span class="tooltipHeader">Source:</span>
 +
    NIH GUIDELINES FOR RESEARCH INVOLVING RECOMBINANT OR SYNTHETIC NUCLEIC ACID MOLECULES. 2013.
 +
<a href="http://osp.od.nih.gov/sites/default/files/NIH_Guidelines.html#_Toc351276292" target="_blank">(Link)</a></span>
-
<span class="intro">The first step of</span> this process was drawing the pathway of the amino acids, including all enzymes and reactions. This was a huge task and we ended up with the pathway seen in figure 1. Second step consisted of finding all the needed constants of the enzyme reactions in the pathway, including around 170 km and Vmax constants found on <a href="http://www.brenda-enzymes.org/" target="_blank">BRENDA.</a> and in the literature. <br><br>
 
-
<span class="intro">The last step of</span> the process was implementing the differential equations made using the pathway, Michaelis-Menten kinetics and our constants in a differential equation solver. We chose to use Berkeley Madonna since this solver solve systems quickly and provides the ability to work with “sliders”, which allow us to see the impact of small changes in constants and equations on our system. <br><br>
+
Further more, it is weakened and thereby not able to
 +
survive in case of leakage. We have also been working with the Odor Free chassis E.coli YYC912, which is a
 +
modified strain, not able to produce indole. This strain is non-pathogen as
 +
<span class="sourceReference">well.</span>
 +
<span class="tooltip">
 +
  <span class="tooltipHeader">Source:</span>
 +
    Genportal, 2006.
 +
<a href="http://www.genoportal.org/bbdb/get.php?q=BBa_J45999" target="_blank">(Link)</a></span>
-
<h4> What did the model tell us?</h4>
+
Our parts, both basic parts and devices, are all taken from
 +
risk group 1 organisms and therefore do not contain nor mimic any virulence factors. This would be indicative of a
 +
very low hazardousness of our system. On the other hand, we have a self-designed protein and the safety of this
 +
brick might need to be considered. To avoid toxicity, we have shuffled the amino acids until the obtained sequence
 +
didn’t resemble any known toxin or other disease causing protein. We have also assayed the toxicity by feeding
 +
<i>C. elegans</i> bacteria producing OneProt (For more information, see our <a href="https://2014.igem.org/Team:SDU-Denmark/Tour42">results page</a>).<br><br>
 +
</p>
 +
 
 +
<h4>Probability</h4>
<p>
<p>
-
To be written.
+
<span class="intro">When analyzing the probability</span> it is important to consider that there always will be an element of uncertainty in the
 +
results. The completion of our project implies the release of GMO to the environment. Even though our GMO will be weakened in 
 +
several ways, the environmental effect of this release cannot be completely foreseen.<br><br>
</p>
</p>
-
<h4>Modelling database</h4>
+
<h4>Risk</h4>
<p>
<p>
-
<span class="intro">Collaborating and helping other</span> teams is a very big part of the iGEM competition. Every year new and better projects are created because it is possible to use what the previous teams have created and use this to make more complex projects – using a collection of bricks to build a new construction. In our opinion this should not only be the case for the wet-lab part of iGEM but also be true for the modelling aspect of iGEM. This is why we suggest making a modelling part registry section on the iGEM page, containing modelling “bricks” created by the iGEM teams all over the world. <br><br>
+
<span class="intro">Our final product would include</span> a group of cellulases, this could mean that there would be a remote risk that, in case of leakage, our bacteria could start to uncontrollably degrade cellulose into glucose for satisfying its
 +
own metabolic requirements. In this sense these bacteria could potentially become a threat for crops and other
 +
plants. To manage this, our idea is to have the cellulases regulated by an inducible promoter, which will
 +
prevent the production of cellulase in the absence of the inducer. In a worst-case scenario this promoter could
 +
mutate to become constitutive active and thereby produce cellulase. Even if this was the case, other safety
 +
mechanisms would still be active, such as the kill switch and the general low environmental stability of E.coli K12. The
 +
probability of all these factors randomly mutating/failing at the same time is almost negligible. We can analyze the
 +
risk of this event by using a risk matrix:<br><br>
-
<span class="intro">To be more specific</span> we want to make it easier to go from pathway to differential equations. This could be achieved by translating the enzymes of the pathways into differential equations only needing the E.C number of the enzyme. As an example we made a proof of concept database on our wiki which is available when using <a href="https://2014.igem.org/Team:SDU-Denmark/Tour35" target="_blank">this link</a>. On the iGEM modelling parts registry it should then be possible to search the enzymes using, the E.C number of the enzyme, the pathway(s) that the enzyme is a part of, the name of the enzyme, or even the most used enzymes (just like the normal parts registry). After choosing an enzyme it should then be possible to open a <a href="https://2014.igem.org/Team:SDU-Denmark/Tour36" target="_blank">page like this</a> and find the needed information, i. e. name, reaction, differential equation, constants and notes about the differential equation regarding what aspects are included and what aspects are excluded (for example inhibition and the amount of substrates and products). Lastly it should be possible to copy the differential equation with the constants inserted to be able to insert it in the wanted model. <br><br>
+
<div class="popupImg alignCenter" style="width:600px" target="_blank" title="Risk matrix: This describes relation between the probability and the hazard of our project. According to this analysis is this risk “yellow”, which means that it is acceptable to work with this project, but some considerations, such as a kill switch, may be considered">Risk matrix: This describes relation between the probability and the hazard of our project. According to this analysis is this risk “yellow”, which means that it is acceptable to work with this project, but some considerations, such as a kill switch, may be considered.
 +
  <img src="https://static.igem.org/mediawiki/2014/b/b7/2014SDUsafety3.PNG" style="width:600px" />
 +
</div><br><br>
-
<span class="intro">Standardization is a very</span> important part of any database and this one is not an exception – all uploaded models should include all necessary elements and look the same. This is why it is important to have a specific uploading procedure and why we have made  <a href="https://2014.igem.org/Team:SDU-Denmark/Tour39" target="_blank">this example</a> of how a team could upload a model to the iGEM modelling part registry. <br><br>
+
<span class="intro">As for the risk</span> for the safety and health of the general public, it is of great concern to avoid the spread of antibiotic
 +
resistance. All our constructs are made on antibiotic-resistant bacteria, which could, potentially, transfer resistance
 +
genes to other bacteria, in case of leakage. This would contribute to the increasing difficulty in fighting so far
 +
controlled infections. To avoid this, we think that in the future these genes could be transferred into a plasmid
 +
developed in our university, which contains the proteins needed to make ribosomes and use <i>E. coli</i> knocked down
 +
for these genes. In this way the bacteria is completely dependent of the plasmid in order to survive, which can be
 +
used as an alternative method of selection.<br><br>
 +
</p>
-
<span class="intro">We have been communicating</span> with both iGEM headquarters and other iGEM teams about the idea of this kind of modelling part registry and we have gotten a lot of positive feedback:<br><br>
+
<h4>Dual use</h4>
 +
<p>
 +
<span class="intro">If the product was to be misused</span> by individuals, groups or countries, they could potentially use this bacterium to
 +
induce the right combination of mutations, in order to get a plant-destruction weapon. We evaluate that the risk
 +
involved in the misuse of our project is actually smaller than the misuse of the cellulase biobrick itself (because
 +
of the kill switch, need of mutation of the promoter, etc.)<br><br>
 +
<span class="intro">The misuse of our protein</span> might be aimed at mutating the protein to make it harmful. We consider, though, that if the aim is to create a harmful protein there are other easier ways, such as starting with a pathogenic protein
 +
or simply designing a protein.<br><br>
 +
<span class="intro">The best way to fight</span> dual use is to try to prevent it by taking biosecurity measures in consideration, like limited
 +
access to laboratories and tracking of orders of gene synthesis.<br><br>
</p>
</p>
-
<center> <a href="https://2014.igem.org/Team:SDU-Denmark/Tour35"><b>Modelling database</b></a> </center>
+
<h4>Risk perspectives: including others</h4>
 +
<p>
 +
<span class="intro">It is our conviction</span> that a good synthetic biologist (and scientist) is one that, besides evaluating the safety of his projects, can include the general public into the discussion. Public opinion has an enormous effect on the feasibility
 +
of a project to succeed, both because the acceptance of the general public can make it easier to receive funding,
 +
but also because of the valuable feedback that can come as a result of the interaction between the general public
 +
and the synthetic biologist. Therefore it is important to <b>communicate</b> effectively and <b>considerate</b>, what might be
 +
perceived as a risk factor. In our case, bacteria and GMOs are often considered as hazardous and not as a food
 +
resource. The fact that many people are not familiar with bacteria and GMO could make the risk perception very high.
 +
To cope with this issue we made our interactive video adventure as an attempt to share the message, inform the
 +
general public and, hopefully, reduce the risk perception of our project.<br><br>
 +
 
 +
<span class="intro">All in all, we believe</span> that, even though there could potentially be some risks related to our project, it is safe enough to continue with our project, especially in the light of the potential and more probable benefits.
 +
 
 +
<br><br><br>
 +
</p>
</html>
</html>
{{:Team:SDU-Denmark/core/footer}}
{{:Team:SDU-Denmark/core/footer}}

Latest revision as of 01:37, 18 October 2014

Safety

"With great power comes great responsibility!" - Voltaire

The role of a synthetic biologist involves the analysis of the biosafety of the systems designed. Biosafety is the prevention of an accidental or unintentional exposure to pathogens, and to analyze this it is useful to evaluate the risk involved in the project which can be expressed as “Risk= Hazard x Probability”. Source: iGEM, 2013: Safety form Resources. (Link)

Hazard

To evaluate the potential hazardousness of our project, we started by looking at the components of the system. Our main chassis, E.coli K12 MG1655 is a non-pathogen E.coli strain. Source: NIH GUIDELINES FOR RESEARCH INVOLVING RECOMBINANT OR SYNTHETIC NUCLEIC ACID MOLECULES. 2013. (Link) Further more, it is weakened and thereby not able to survive in case of leakage. We have also been working with the Odor Free chassis E.coli YYC912, which is a modified strain, not able to produce indole. This strain is non-pathogen as well. Source: Genportal, 2006. (Link) Our parts, both basic parts and devices, are all taken from risk group 1 organisms and therefore do not contain nor mimic any virulence factors. This would be indicative of a very low hazardousness of our system. On the other hand, we have a self-designed protein and the safety of this brick might need to be considered. To avoid toxicity, we have shuffled the amino acids until the obtained sequence didn’t resemble any known toxin or other disease causing protein. We have also assayed the toxicity by feeding C. elegans bacteria producing OneProt (For more information, see our results page).

Probability

When analyzing the probability it is important to consider that there always will be an element of uncertainty in the results. The completion of our project implies the release of GMO to the environment. Even though our GMO will be weakened in several ways, the environmental effect of this release cannot be completely foreseen.

Risk

Our final product would include a group of cellulases, this could mean that there would be a remote risk that, in case of leakage, our bacteria could start to uncontrollably degrade cellulose into glucose for satisfying its own metabolic requirements. In this sense these bacteria could potentially become a threat for crops and other plants. To manage this, our idea is to have the cellulases regulated by an inducible promoter, which will prevent the production of cellulase in the absence of the inducer. In a worst-case scenario this promoter could mutate to become constitutive active and thereby produce cellulase. Even if this was the case, other safety mechanisms would still be active, such as the kill switch and the general low environmental stability of E.coli K12. The probability of all these factors randomly mutating/failing at the same time is almost negligible. We can analyze the risk of this event by using a risk matrix:

Risk matrix: This describes relation between the probability and the hazard of our project. According to this analysis is this risk “yellow”, which means that it is acceptable to work with this project, but some considerations, such as a kill switch, may be considered.


As for the risk for the safety and health of the general public, it is of great concern to avoid the spread of antibiotic resistance. All our constructs are made on antibiotic-resistant bacteria, which could, potentially, transfer resistance genes to other bacteria, in case of leakage. This would contribute to the increasing difficulty in fighting so far controlled infections. To avoid this, we think that in the future these genes could be transferred into a plasmid developed in our university, which contains the proteins needed to make ribosomes and use E. coli knocked down for these genes. In this way the bacteria is completely dependent of the plasmid in order to survive, which can be used as an alternative method of selection.

Dual use

If the product was to be misused by individuals, groups or countries, they could potentially use this bacterium to induce the right combination of mutations, in order to get a plant-destruction weapon. We evaluate that the risk involved in the misuse of our project is actually smaller than the misuse of the cellulase biobrick itself (because of the kill switch, need of mutation of the promoter, etc.)

The misuse of our protein might be aimed at mutating the protein to make it harmful. We consider, though, that if the aim is to create a harmful protein there are other easier ways, such as starting with a pathogenic protein or simply designing a protein.

The best way to fight dual use is to try to prevent it by taking biosecurity measures in consideration, like limited access to laboratories and tracking of orders of gene synthesis.

Risk perspectives: including others

It is our conviction that a good synthetic biologist (and scientist) is one that, besides evaluating the safety of his projects, can include the general public into the discussion. Public opinion has an enormous effect on the feasibility of a project to succeed, both because the acceptance of the general public can make it easier to receive funding, but also because of the valuable feedback that can come as a result of the interaction between the general public and the synthetic biologist. Therefore it is important to communicate effectively and considerate, what might be perceived as a risk factor. In our case, bacteria and GMOs are often considered as hazardous and not as a food resource. The fact that many people are not familiar with bacteria and GMO could make the risk perception very high. To cope with this issue we made our interactive video adventure as an attempt to share the message, inform the general public and, hopefully, reduce the risk perception of our project.

All in all, we believe that, even though there could potentially be some risks related to our project, it is safe enough to continue with our project, especially in the light of the potential and more probable benefits.